Volume 17, Number 3—March 2011
Letter
Mycobacterium mageritense Pulmonary Disease in Patient with Compromised Immune System
Table
In vitro activity of 23 isolates of Mycobacterium mageritense, United States, 2009*
Antimicrobial agent |
No. isolates tested |
MICs of current isolate, μg/mL |
Intermediate breakpoint, μg/mL |
MIC range, μg/mL |
MIC50, μg/mL |
MIC90, μg/mL |
% S/I |
---|---|---|---|---|---|---|---|
Amikacin | 23 | 8 | 32 | <1–32 | 16 | 32 | 100 |
Cefoxitin | 23 | 16 | 32–64 | <8–256 | 32 | 64 | 91 |
Ciprofloxacin | 23 | 0.25 | 2 | <0.25–0.5 | 0.25 | 0.5 | 100 |
Clarithromycin† | 23 | 8 | 4 | 1–>64 | >32 | >64 | 4 |
Doxycycline | 22 | 1 | 2–8 | 0.25–>64 | 8 | >32 | 50 |
Imipenem | 22 | 4 | 8 | <0.5–8 | 2 | 4 | 100 |
Linezolid | 22 | 4 | 16 | <2–16 | 4 | 8 | 100 |
Sulfamethoxazole | 21 | 4 | 32 | <2–32 | 8 | 32 | 100 |
Trimethoprim/sulfamethoxazole | 6 | 1/19 | 2/38‡ | <0.25/4.8– 2/38 | 0.5/9.5 | 2/38 | 100 |
Tobramycin | 23 | <2 | 8 | 2–64 | >16 | >32 | 30 |
Tigecycline | 5 | 0.12 | –§ | <0.03–0.12 | 0.06 | 0.12 | NA |
References
- Domenech P, Jimenez MS, Menendez MC, Bull TJ, Samper S, Manrique A, Mycobacterium mageritense sp. nov. Int J Syst Bacteriol. 1997;47:535–40. DOIPubMedGoogle Scholar
- Wallace RJ, Brown-Elliott BA, Hall L, Roberts G, Wilson RW, Mann LB, Clinical and laboratory features of Mycobacterium mageritense. J Clin Microbiol. 2002;40:2930–5. DOIPubMedGoogle Scholar
- Appelgren P, Farnebo F, Dotevall L, Studahl M, Jönsson B, Petrini B. Late-onset posttraumatic skin and soft tissue infections caused by rapid-growing mycobacteria in tsunami survivors. Clin Infect Dis. 2008;47:e11–6. DOIPubMedGoogle Scholar
- Gira AK, Reisenauer AH, Hammock L, Nadiminti U, Macy JT, Reeves A, Furunculosis due to Mycobacterium mageritense associated with footbaths at a nail salon. J Clin Microbiol. 2004;42:1813–7. DOIPubMedGoogle Scholar
- Miki M, Shimizukawa M, Okayama H, Kazumi Y. Case of pulmonary Mycobacterium mageritense infection: the difficulty of differential diagnosis of granulomatous lung disease. Kekkaku. 2007;82:189–94.PubMedGoogle Scholar
- Steingrube VA, Gibson JL, Brown BA, Zhang Y, Wilson RW, Rajagopalan M, PCR amplification and restriction endonuclease analysis of a 65-kiloDalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria [ERRATUM 1995;33:1686]. J Clin Microbiol. 1995;33:149–53.PubMedGoogle Scholar
- Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, Pfyffer GE, Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard. NCCLS Document M24-A. Wayne (PA): Clinical and Laboratory Standards Institute; 2003.
- Adékambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late pigmented rapidly growing mycobacteria. J Clin Microbiol. 2003;41:5699–708. DOIPubMedGoogle Scholar
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. DOIPubMedGoogle Scholar
- Nash KA, Andini N, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother. 2006;50:3476–8. DOIPubMedGoogle Scholar